Articles and Videos
Loading...
July 5, 2022
The Dales Report – InMed Pharmaceuticals Unveils Industry Leading Portfolio
Jerry P. Griffin, VP of Sales and Marketing at BayMedica, InMed's subsidiary, is interviewed by Shadd Dales of the The Dales Report to talk about...
Source: The Dales Report
July 4, 2022
Pharma Tech Outlook: InMed Introduces THCV Into the Health and Wellness Industry
InMed's THCV will bring ample opportunity to the health sector to scale up in the market. Read full story via Pharma Tech Outlook.
July 3, 2022
What are cannabinoid analogs?
Cannabinoid analogs are novel cannabinoid compounds that are slightly modified from the naturally occurring cannabinoids in the plant. Since they have a new molecular structure...
June 29, 2022
The Intersection Between Medical and Health & Wellness: Force For Knowledge Cannabis Symposium Panel Discussion
InMed Pharmaceuticals' Dr. Shane Johnson and Radicle Science’s Dr. Jeff Chen join the Force Family Office's Force For Knowledge Cannabis Symposium: The Intersection Between Medical...
Source: Force Family Office
June 22, 2022
InMed Pharmaceuticals publicizes new peer-reviewed study
New academic journal spotlights potential for rare cannabinoids to treat skin conditions Read full article via Mugglehead Magazine. Excerpt: Less popular cannabinoids such as tetrahydrocannabivarin...
June 17, 2022
Benzinga All Access: Guest Speaker Shane Johnson, BayMedica GM
Dr. Shane Johnson, SVP and GM of BayMedica, InMed's subsidiary, joins Benzinga's All Access Conference on June 17, 2022. Dr. Johnson talks about how manufacturing...
Source: Benzinga All Access